Trametinib

Red

Brand Name(s):Mekinist

Indication:Metastatic melanoma with a BRAF V600 mutation
Non-small cell lung cancer with a BRAF V600 mutation.
Stage III Melanoma with a BRAF V600 mutation, following complete resection.

Rationale:1,2,3

Considered:Dec-15

Review Date:Aug-23

Comments:
Drug Safety Update March 2016
Risk of gastrointestinal perforation and colitis:
https://www.gov.uk/drug-safety-update/trametinib-mekinist-risk-of-gastrointestinal-perforation-and-colitis